LaNova Medicines Initiates Pivotal Clinical Trial for LM-108 in China
-
2024-12-20
-
Share:
SHANGHAI, December, 2024 – LaNova Medicines Ltd. announced the initiation of its first pivotal clinical trial for LM-108 (anti-CCR8 mAb) in China.
This clinical study (CTR20250219) is a Phase II, single-arm, multicenter, open-label trial primarily evaluating the efficacy and safety of LM-108 in combination with Toripalimab in patients with unresectable or metastatic MSI-H/dMMR advanced solid tumors who have failed prior treatment with anti-PD-1/PD-L1 therapies.